2021
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
Kim A, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, Chiang V, Smith K, Williams B, Mohammadi A, Judy K, Sloan A, Tovar-Spinoza Z, Baumgartner J, Hadjipanayis C, Leuthardt E. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery 2021, 89: s16-s16. PMCID: PMC8600280, DOI: 10.1093/neuros/nyaa071_s016.Peer-Reviewed Original ResearchManagement of Brain Metastases
Collier E, Chiang V, Goldberg S. Management of Brain Metastases. Current Cancer Research 2021, 115-137. DOI: 10.1007/978-3-030-74028-3_6.Peer-Reviewed Original ResearchBrain metastasesSystemic therapyLocal therapyAsymptomatic brain metastasesNew systemic therapiesSource of morbidityInclusion of patientsMalignant brain tumorsQuality of lifeNew cancer treatmentsSignificant morbidityWorse prognosisPatient survivalCNS diseaseLung cancerClinical trialsBrain tumorsMetastasisNSCLCTherapyCancer treatmentSmall molecule drugsFrequent originMorbidityTreatment
2016
BMET-24. LASER ABLATION AFTER STEREOTACTIC RADIOSURGERY (LAASR) – RESULTS OF A MULTI-CENTERED PROSPECTIVE STUDY
Chiang V, Dietrich J, Tatter S, Mohammadi A, Leuthardt E, Chamoun R, Judy K, Barnett G, Ahluwalia M. BMET-24. LASER ABLATION AFTER STEREOTACTIC RADIOSURGERY (LAASR) – RESULTS OF A MULTI-CENTERED PROSPECTIVE STUDY. Neuro-Oncology 2016, 18: vi31-vi31. DOI: 10.1093/neuonc/now212.124.Peer-Reviewed Original ResearchKarnofsky performance statusProgression-free survivalProgressive brain metastasesOverall survivalRadiation necrosisBrain metastasesMedian Karnofsky performance statusMedian KPS scorePrimary tumor pathologyPrior stereotactic radiosurgeryStereotactic radiosurgery resultsQuality of lifeOutcomes of useRN patientsSteroid usageFree survivalHospital stayKPS scorePerformance statusRANO criteriaSecondary outcomesPrimary outcomeFACT-BrRecurrent tumorsTM patients